Literature DB >> 3290250

Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.

R A Liddle1, R J Rushakoff, E T Morita, L Beccaria, J D Carter, I D Goldfine.   

Abstract

It is known that the ingestion of glucose alone causes a greater increase in plasma glucose levels than ingestion of the same amount of glucose given with other nutrients. Since physiological plasma concentrations of cholecystokinin (CCK) prolong gastric emptying, it is proposed that after a meal, CCK may modify plasma glucose levels by delaying glucose delivery to the duodenum. To evaluate the effect of CCK on oral glucose tolerance, plasma CCK, insulin, and glucose levels and gastric emptying rates were measured in eight normal males before and after the ingestion of 60 g glucose with the simultaneous infusion of either saline or one of two doses of CCK-8 (12 or 24 pmol/kg per h). Gastric emptying rates were measured by gamma camera scintigraphy of technetium 99m sulfur colloid and plasma CCK levels were measured by a sensitive and specific bioassay. Basal CCK levels averaged 1.0 +/- 0.1 pM (mean +/- SEM, n = 8) and increased to 7.1 +/- 1.1 pM after a mixed liquid meal. After glucose ingestion, but without CCK infusion, CCK levels did not change from basal, and the gastric emptying t1/2 was 68 +/- 3 min. Plasma glucose levels increased from basal levels of 91 +/- 3.9 mg/dl to peak levels of 162 +/- 11 mg/dl and insulin levels increased from 10.7 +/- 1.8 microU/ml to peak levels of 58 +/- 11 microU/ml. After glucose ingestion, with CCK infused at 24 pmol/kg per h, plasma CCK levels increased to 8 pM and the gastric emptying t1/2 increased to 148 +/- 16 min. In concert with this delay in gastric emptying, peak glucose levels rose to only 129 +/- 17 mg% and peak insulin levels rose to only 24.2 +/- 4.2 microU/ml. With CCK at 12 pmol/kg per h, similar but less dramatic changes were seen. To demonstrate that endogenous CCK could modify the plasma glucose and insulin responses to oral glucose, oral glucose was given with 50 g of lipid containing long-chain triglycerides. This lipid increased peak CCK levels to 3.7 +/- 0.9 pM. Concomitant with this rise in CCK was a delay in gastric emptying and a lowering of plasma glucose and insulin values. To confirm that CCK reduced hyperglycemia by its effect on gastric motility, 36 g glucose was perfused directly into the duodenum through a nasal-duodenal feeding tube in four subjects. With duodenal perfusion of glucose, there was no change in plasma CCK levels, but plasma glucose levels increased from basal levels of 93+/-5 to 148+/-6 mg/dl and insulin levels rose from 10.6+/-3.5 to 29.5+/-5.2 microU/ml. When CCK was infused at 24 pmol/kg per h, neither the plasma glucose nor insulin responses to the duodenal administration of glucose were modified. Thus we conclude that CCK, in physiological concentrations, delays gastric emptying, slows the delivery of glucose to the duodenum, and reduces postprandial hyperglycemia. These data indicate, therefore, that CCK has a significant role in regulating glucose homeostasis in human.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290250      PMCID: PMC442610          DOI: 10.1172/JCI113505

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man.

Authors:  J Dupre; S A Ross; D Watson; J C Brown
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

2.  Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin.

Authors:  V Mutt; J E Jorpes
Journal:  Eur J Biochem       Date:  1968-10-17

3.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Authors:  R A Liddle; I D Goldfine; M S Rosen; R A Taplitz; J A Williams
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

4.  Glucose, glycine and diglycine in test meals at stimuli to a duodenal osmoreceptor slowing gastric emptying.

Authors:  G R Barker; G M Cochrane; G A Corbett; J F Dufton; J N Hunt; S K Roberts
Journal:  J Physiol       Date:  1978-10       Impact factor: 5.182

5.  Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans.

Authors:  R J Rushakoff; I D Goldfine; J D Carter; R A Liddle
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

6.  Effects of cholecystokinin (CCK)-4, nonsulfated CCK-8, and sulfated CCK-8 on pancreatic somatostatin, insulin, and glucagon secretion in the dog: studies in vitro.

Authors:  K Hermansen
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

7.  Regulation of gastric emptying in humans by cholecystokinin.

Authors:  R A Liddle; E T Morita; C K Conrad; J A Williams
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs.

Authors:  R H Unger; H Ketterer; J Dupré; A M Eisentraut
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

9.  Effects of cholecystokinin, gastric inhibitory polypeptide, and secretin on insulin and glucagon secretion in rats.

Authors:  J Szecówka; P E Lins; S Efendić
Journal:  Endocrinology       Date:  1982-04       Impact factor: 4.736

10.  Bioactivity of cholecystokinin analogues: CCK-8 is not more potent than CCK-33.

Authors:  T E Solomon; T Yamada; J Elashoff; J Wood; C Beglinger
Journal:  Am J Physiol       Date:  1984-07
View more
  14 in total

1.  The role of CCK8 in the inhibition of glucose production.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Alan D Cherrington
Journal:  Cellscience       Date:  2009-10-27

Review 2.  Development of minimally invasive techniques for management of medically-complicated obesity.

Authors:  Farzin Rashti; Ekta Gupta; Suzan Ebrahimi; Timothy R Shope; Timothy R Koch; Christopher J Gostout
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 3.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

4.  Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects.

Authors:  M Horowitz; M A Edelbroek; J M Wishart; J W Straathof
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

5.  Gastric emptying in Mexican Americans compared to non-Hispanic whites.

Authors:  J G Schwartz; C A McMahan; G M Green; W T Phillips
Journal:  Dig Dis Sci       Date:  1995-03       Impact factor: 3.199

6.  Cholecystokinin is not a physiological regulator of gastric pepsin secretion in rats.

Authors:  S Kawabata; S Kanayama; Y Shinomura; S Kondo; Y Matsuzawa
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

7.  Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide.

Authors:  M Fried; W Schwizer; C Beglinger; U Keller; J B Jansen; C B Lamers
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

8.  Reduced postprandial blood glucose levels in recently diagnosed non-insulin-dependent diabetics secondary to pharmacologically induced delayed gastric emptying.

Authors:  W T Phillips; J G Schwartz; C A McMahan
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

9.  Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin.

Authors:  A A Young; B Gedulin; W Vine; A Percy; T J Rink
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

10.  Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action.

Authors:  Michael James Zema
Journal:  Core Evid       Date:  2012-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.